The company’s Phase IIb trial found the therapy, N6LS, was able to maintain viral loads below a detectable threshold.

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced positive findings from the company’s EMBRACE phase IIb study.

In a story of collaboration and community, researchers identified intergenerational epigenetic changes caused by war and ...

A yearly injection to protect against HIV is safe and shows promise as a prevention method with long-lasting effects, according to the results of a clinical trial published in The Lancet journal.

UCSF researchers are the first to confirm that this approach is effective for the patients who need it most. Patients who ...

Two more people have been potentially cured of HIV after receiving stem cell transplants to treat blood cancer or bone marrow ...

SLIM LIVER was the first clinical trial to test semaglutide as a treatment for MASLD in people living with HIV. MASLD, previously known as non-alcoholic fatty liver disease (NAFLD), is a common and ...

Pamela Bjorkman of the California Institute of Technology won the prize for ‘offering new hope in the fight against ...

Immunocore’s big swing for a functional HIV cure has cleared its first hurdle. | Immunocore’s big swing for a functional HIV ...

An American biochemist whose research has helped scientists make inroads on treating coronavirus and HIV has won this year’s ...

By analyzing genes encoding B-cell and T-cell receptors, the model could screen for conditions like HIV, type 1 diabetes, and ...

Blood cells and immune cells are made in the bone marrow ... treatable conditions such as HIV infection and herpes. They also include often deadly illnesses such as rabies and Ebola. Depending on the ...